Margaret K. Callahan

50.6k total citations · 10 hit papers
166 papers, 13.6k citations indexed

About

Margaret K. Callahan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Margaret K. Callahan has authored 166 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Oncology, 48 papers in Immunology and 45 papers in Molecular Biology. Recurrent topics in Margaret K. Callahan's work include Cancer Immunotherapy and Biomarkers (102 papers), CAR-T cell therapy research (58 papers) and Immunotherapy and Immune Responses (34 papers). Margaret K. Callahan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (102 papers), CAR-T cell therapy research (58 papers) and Immunotherapy and Immune Responses (34 papers). Margaret K. Callahan collaborates with scholars based in United States, Germany and Spain. Margaret K. Callahan's co-authors include Jedd D. Wolchok, Michael A. Postow, Michael A. Postow, Paul B. Chapman, James P. Allison, Katherine S. Panageas, Parisa Momtaz, Paolo A. Ascierto, Richard D. Carvajal and Emiliano Calvo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Margaret K. Callahan

159 papers receiving 13.4k citations

Hit Papers

Immune Checkpoint Blockade in Cancer Therapy 2012 2026 2016 2021 2015 2020 2015 2016 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune Checkpoint Blockade in Cancer Therapy
    2015 2.1k citations Michael A. Postow, Margaret K. Callahan et al. Journal of Clinical Oncology profile →
  2. Immune-related adverse events of checkpoint inhibitors
    2020 931 citations Margaret K. Callahan et al. profile →
  3. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
    2015 808 citations Parisa Momtaz, Michael A. Postow et al. Journal of Clinical Oncology profile →
  4. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
    2016 773 citations Margaret K. Callahan, Agnès Viale et al. Nature Communications profile →
  5. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
    2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. profile →
  6. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
    2014 537 citations Margaret K. Callahan, Jedd D. Wolchok et al. profile →
  7. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
    2016 511 citations Padmanee Sharma, Margaret K. Callahan et al. profile →
  8. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
    2012 410 citations Christine A. Pratilas, Margaret K. Callahan et al. profile →
  9. Immune Modulation in Cancer with Antibodies
    2013 403 citations Michael A. Postow, Margaret K. Callahan et al. profile →
  10. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
    2018 374 citations Mark J. Bluth, Hikmat Al‐Ahmadie et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret K. Callahan United States 45 10.2k 5.0k 3.3k 2.2k 1.3k 166 13.6k
Éric Tartour France 65 8.3k 0.8× 8.6k 1.7× 4.1k 1.2× 1.7k 0.8× 1.3k 1.0× 263 15.3k
Michele W.L. Teng Australia 56 9.2k 0.9× 8.3k 1.7× 3.6k 1.1× 1.9k 0.8× 833 0.6× 95 15.0k
Taku Okazaki Japan 45 12.4k 1.2× 11.9k 2.4× 2.8k 0.8× 1.8k 0.8× 1.1k 0.8× 70 20.0k
Scott E. Strome United States 48 6.9k 0.7× 6.1k 1.2× 2.1k 0.6× 1.5k 0.7× 1.4k 1.1× 144 11.5k
Jonathan Cebon Australia 62 6.3k 0.6× 6.6k 1.3× 4.7k 1.4× 1.2k 0.5× 700 0.5× 278 13.6k
Erin Murphy United States 22 6.2k 0.6× 8.4k 1.7× 3.0k 0.9× 1.5k 0.7× 2.0k 1.6× 49 13.9k
Koji Tamada Japan 54 10.6k 1.0× 11.8k 2.3× 2.8k 0.8× 1.4k 0.6× 821 0.6× 147 17.4k
Hiroyoshi Nishikawa Japan 54 8.1k 0.8× 9.1k 1.8× 2.9k 0.9× 1.6k 0.7× 833 0.6× 187 14.3k
Dallas B. Flies United States 38 9.4k 0.9× 10.6k 2.1× 2.3k 0.7× 1.3k 0.6× 725 0.6× 65 14.9k
Haidong Dong United States 60 13.7k 1.3× 11.4k 2.3× 3.4k 1.0× 3.5k 1.6× 1.6k 1.2× 182 19.8k

Countries citing papers authored by Margaret K. Callahan

Since Specialization
Citations

This map shows the geographic impact of Margaret K. Callahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret K. Callahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret K. Callahan more than expected).

Fields of papers citing papers by Margaret K. Callahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret K. Callahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret K. Callahan. The network helps show where Margaret K. Callahan may publish in the future.

Co-authorship network of co-authors of Margaret K. Callahan

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret K. Callahan. A scholar is included among the top collaborators of Margaret K. Callahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret K. Callahan. Margaret K. Callahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Smithy, James W., et al.. (2025). Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis. Nature Communications. 16(1). 6619–6619. 1 indexed citations
3.
Smithy, James W., Ronak Shah, Matthew Adamow, et al.. (2024). Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clinical Cancer Research. 30(16). 3407–3415. 4 indexed citations
4.
Callahan, Margaret K., Asim Amin, Frederic J. Kaye, et al.. (2024). Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). Journal for ImmunoTherapy of Cancer. 12(2). e007883–e007883. 7 indexed citations
5.
Adamow, Matthew, Colleen Maher, Michael A. Postow, et al.. (2023). A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy. Cell Reports Methods. 3(8). 100546–100546. 3 indexed citations
6.
Atkinson, Thomas M., Jennifer L. Hay, Soo Young Kim, et al.. (2023). Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. The Oncologist. 28(4). 351–357. 6 indexed citations
7.
Smithy, James W., Colleen Maher, Alexander N. Shoushtari, et al.. (2023). Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).. Journal of Clinical Oncology. 41(16_suppl). 9517–9517.
8.
Chapman, Paul B., Mark Klang, Michael A. Postow, et al.. (2023). Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib. Cancer Research Communications. 3(12). 2447–2454. 4 indexed citations
9.
Vanguri, R., James W. Smithy, Yanyun Li, et al.. (2023). Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology. 261(3). 349–360. 6 indexed citations
10.
Friedman, Claire F., Christine N. Spencer, Christopher R. Cabanski, et al.. (2022). Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for ImmunoTherapy of Cancer. 10(1). e003853–e003853. 30 indexed citations
11.
Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884. 39 indexed citations
12.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616. 178 indexed citations
13.
Callahan, Margaret K., Michael A. Postow, & Jedd D. Wolchok. (2016). Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 44(5). 1069–1078. 357 indexed citations
14.
Abdel‐Wahab, Omar, Virginia M. Klimek, Agnès Viale, et al.. (2014). Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery. 4(5). 538–545. 59 indexed citations
15.
Ryder, Mabel, Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok, & James A. Fagin. (2014). Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine Related Cancer. 21(2). 371–381. 344 indexed citations
16.
Callahan, Margaret K. & Jedd D. Wolchok. (2013). At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of Leukocyte Biology. 94(1). 41–53. 271 indexed citations
17.
Callahan, Margaret K., Gregg Masters, Christine A. Pratilas, et al.. (2013). Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research. 2(1). 70–79. 91 indexed citations
18.
Callahan, Margaret K., Elizabeth A. Wohlfert, Antoine Ménoret, & Pramod K. Srivastava. (2006). Heat Shock Up-Regulates lmp2 and lmp7 and Enhances Presentation of Immunoproteasome-Dependent Epitopes. The Journal of Immunology. 177(12). 8393–8399. 33 indexed citations
19.
Wohlfert, Elizabeth A., Margaret K. Callahan, & Robert B. Clark. (2004). Resistance to CD4+CD25+ Regulatory T Cells and TGF-β in Cbl-b−/− Mice. The Journal of Immunology. 173(2). 1059–1065. 105 indexed citations
20.
Cheryl, S., Lourens J.D. Zaneveld, Linda Munson, Margaret K. Callahan, & A. P. Byers. (1996). Efficacy, safety, and reversibility of a bisdiamine male-directed oral contraceptive in gray wolves (Canis lupus). Journal of Zoo and Wildlife Medicine. 27(4). 501–506. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Tartour Breakdown of academic impact, for papers by Michele W.L. Teng Breakdown of academic impact, for papers by Taku Okazaki Breakdown of academic impact, for papers by Scott E. Strome Breakdown of academic impact, for papers by Jonathan Cebon Breakdown of academic impact, for papers by Erin Murphy Breakdown of academic impact, for papers by Koji Tamada Breakdown of academic impact, for papers by Hiroyoshi Nishikawa Breakdown of academic impact, for papers by Dallas B. Flies Breakdown of academic impact, for papers by Haidong Dong
Rankless by CCL
2026